Please login to the form below

Not currently logged in
Email:
Password:

Danish biopharma company wins R&D award

Zealand Pharma has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan

Zealand Pharma A/S has won the 2008 European Research & Development Company of the Year Award from Frost & Sullivan, a global growth consulting firm. Zealand Pharma is involved in the discovery and development of innovative peptide-based drugs. It has been ranked top for demonstrating technological superiority in its field through market analysis based on interviews and extensive secondary research.

"It is an honour to be recognised by Frost & Sullivan", said David Solomon, head of Zealand Pharma A/S. "The European Research & Development Award highlights our company's ongoing achievements in its path to commercialising peptide-based drugs that treat unmet medical need in the areas of diabetes, metabolism, cardiovascular disease and gastrointestinal disorders such as Crohn's disease." 

The award recognises the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.

All of Zealand's products target diseases and symptoms of significant unmet clinical need and commercial potential. 

Since 1999, Zealand's scientists have built a pipeline that includes five compounds in clinical development, three of which have been out-licensed to pharmaceutical companies, sanofi-aventis, Wyeth and Helsinn Healthcare.

18th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics